ANDREI THOMAS-TIKHONENKO, PhD – ACCELERATION INITIATIVE – HIGH-RISK PEDIATRIC CANCERS – NEUROBLASTOMA AND DIFFUSE MIDLINE GLIOMA

For this work, Dr. Andrei Thomas-Tikhonenko chose two malignancies, based on the existence of validated targets, the availability of high-quality RNA-Seq data and primary samples, strong expertise of collaborators, and – last but not least – urgent and unmet clinical need: 

Neuroblastoma: Children diagnosed with neuroblastoma are typically younger than 5 years old. Most high-risk neuroblastoma patients die despite intensive cytotoxic therapies, and survivors are burdened with treatment-related long-term effects. A child diagnosed with neuroblastoma today is subjected to a highly intensive regimen of toxic chemotherapeutics, radiation therapy, and an immunotherapy that, while effective, is toxic, with pain and anaphylaxis commonly leading to drug discontinuation. Return of the disease still occur sin at least half of the treated patients. 

Diffuse Midline Glioma: Pediatric brain tumors are a leading cause of cancer death in children in the U.S. and diffuse midline glioma (DMG) is one of the most defiant to traditional therapies and these tumors can also be impossible to surgically remove. Currently, there are no effective standard of care therapies for DMG, despite decades of clinical trials. Children affected by DMG nearly universally succumb to the disease within 8-10 months of diagnosis. 

Andrei Thomas-Tikhonenko, PhD, is a CureSearch Acceleration Initiative Awardee conducting research at the Children’s Hospital of Philadelphia. Pediatric cancers, both hematologic and solid, typically have low mutation burden. This could make them invisible to the immune system which is trained to recognize foreign molecules. Therefore, immune checkpoint inhibitors, which have revolutionized cancer treatments in adults, have gained virtually no traction in the realm of childhood malignancies. Antibody-based immunotherapies like CAR T-cell therapy use markers on the surface of cancer cells that differentiate them from normal cells as targets for the immune system. Determining markers that are different from normal cells is essential so that the therapy is tumor-specific and does not damage normal cells. In many tumors, because they are derived from our own cells, it can be hard to find such markers. Dr. Thomas-Tikhonenko and his colleagues will identify novel immunotherapy targets resulting from a process called aberrant splicing. This process results in protein variants that are not found in normal cells. Because these altered cell surface proteins are not found on normal cells, they are an excellent, specific target for immunotherapy. Therapeutics that are developed during this project to recognize these cancer-specific cell-surface proteins will be able to either direct the immune system to destroy cancer cells or deliver therapeutics to the tumor while minimizing damage to normal cells resulting in fewer instances of dose-limiting toxicity and more effective therapy. 

Project Update: The team is ahead of schedule in developing medProF-directed immunotherapeutics that will allow them to target pediatric solid tumor cancers with a specificity that existing treatments do not possess. In 2023, Dr. Andrei Thomas-Tikhonenko’s team will start generating monoclonal antibodies/single-chain variable fragments specific to these immunotherapeutics.